Home > Insider Trading > Filing (0000874015-18-000019)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874015	Ionis Pharmaceuticals Inc	IONS	Pharmaceutical Preparations (2834)	330336973

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1073387	Frank C Bennett	C/O Ionis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad CA 92010	Svp, Antisense Research	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-01-15	6,663	$0.00	21,810	No	4	M	Direct
Common Stock	Disposition	2018-01-16	2,696	$51.76	19,114	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Acquisiton	2018-01-15	12,137	$0.00	12,137	$0.00
Common Stock	Restricted Stock Units	Disposition	2018-01-15	6,663	$0.00	6,663	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
12,137			No	4	A	Direct
10,148			No	4	M	Direct

Footnotes

Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.
The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.760 to $51.761, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.
Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.